Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Asa BioSciences LLC
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Future Algesics
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
ASN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eliapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FA-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sivopixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 Receptor for Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TCR-1672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2021: BELLUS Health convenes virtual alyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937
Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine “TCR1672” filed with and accepted by FDA
Sep 23, 2021: BELLUS Health announces completion of patient enrollment in SOOTHE phase 2b trial for refractory chronic cough and BLUEPRINT phase 2a trial for chronic pruritus associated with atopic dermatitis
Sep 13, 2021: BELLUS Health announces positive interim alysis from the phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough
Sep 06, 2021: Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough
Aug 23, 2021: BELLUS Health to report additiol RELIEF data in an oral presentation at the European Respiratory Society Intertiol Congress 2021
Aug 03, 2021: Evotec SE: Positive phase IIb data for investigatiol P2X3 antagonist in patients with refractory chronic cough
May 10, 2021: BELLUS Health to present at the American Thoracic Society 2021 Intertiol Conference
Mar 03, 2021: MSD files refractory cough medicine in Japan
Mar 01, 2021: U.S. FDA accepts Merck’s gefapixant New Drug Application for review
Jan 14, 2021: BELLUS Health to present at the Eleventh Intertiol Virtual Cough Symposium
Dec 14, 2020: BELLUS Health announces first patient dosed in its phase 2 BLUEPRINT trial of BLU-5937 for the treatment of chronic pruritus associated with atopic dermatitis
Dec 08, 2020: BELLUS Health announces first patient dosed in its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough
Sep 09, 2020: Merck’s gefapixant decreases chronic cough frequency in Phase III trials
Sep 08, 2020: BELLUS Health announces design for its phase 2b Ttial with BLU-5937 in refractory Chronic Cough
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Asana BioSciences LLC, 2021
Pipeline by Bayer AG, 2021
Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2021
Pipeline by BELLUS Health Inc, 2021
Pipeline by Future Analgesics, 2021
Pipeline by Integral Molecular Inc, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Neurim Pharmaceuticals Ltd, 2021
Pipeline by Ossianix Inc, 2021
Pipeline by Shionogi & Co Ltd, 2021
Pipeline by Sino Biopharmaceutical Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021